Every Biosimilar Should Have Its Own Medicare Pay Code, CMS Told
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz and other biosimilar stakeholders react at a public meeting to indications that CMS might be planning to put multiple biosimilars into a single Medicare billing code, meaning they would all be reimbursed at the same amount, when they reference the same innovator product.
You may also be interested in...
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.
GSK Is Third Major Inhaler Maker To Cap Copays; Will Teva Follow?
It might make sense from a competitive standpoint for Teva to join the trend. That’s the way it happened in the insulin category.